Literature DB >> 26083533

Validation of functional imaging as a biomarker for radiation treatment response.

C Jentsch1,2,3, B Beuthien-Baumann1,3,4, E G C Troost1,2,3,4, G Shakirin5.   

Abstract

Major advances in radiotherapy techniques, increasing knowledge of tumour biology and the ability to translate these advances into new therapeutic approaches are important goals towards more individualized cancer treatment. With the development of non-invasive functional and molecular imaging techniques such as positron emission tomography (PET)-CT scanning and MRI, there is now a need to evaluate potential new biomarkers for tumour response prediction, for treatment individualization is not only based on morphological criteria but also on biological tumour characteristics. The goal of individualization of radiotherapy is to improve treatment outcome and potentially reduce chronic treatment toxicity. This review gives an overview of the molecular and functional imaging modalities of tumour hypoxia and tumour cell metabolism, proliferation and perfusion as predictive biomarkers for radiation treatment response in head and neck tumours and in lung tumours. The current status of knowledge on integration of PET/CT/MRI into treatment management and bioimage-guided adaptive radiotherapy are discussed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26083533      PMCID: PMC4628525          DOI: 10.1259/bjr.20150014

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  107 in total

1.  Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?

Authors:  M Regier; T Derlin; D Schwarz; A Laqmani; F O Henes; M Groth; J-H Buhk; H Kooijman; G Adam
Journal:  Eur J Radiol       Date:  2011-12-23       Impact factor: 3.528

2.  Can "early" and "late"18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy?

Authors:  Paola Castaldi; Vittoria Rufini; Francesco Bussu; Francesco Miccichè; Nicola Dinapoli; Rosa Autorino; Mariaelena Lago; Eugenio De Corso; Giovanni Almadori; Jacopo Galli; Gaetano Paludetti; Alessandro Giordano; Vincenzo Valentini
Journal:  Radiother Oncol       Date:  2012-03-27       Impact factor: 6.280

3.  Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.

Authors:  M Lonneux; G Lawson; C Ide; R Bausart; M Remacle; S Pauwels
Journal:  Laryngoscope       Date:  2000-09       Impact factor: 3.325

4.  Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer.

Authors:  H Minn; M Lapela; P J Klemi; R Grénman; S Leskinen; P Lindholm; J Bergman; E Eronen; M Haaparanta; H Joensuu
Journal:  J Nucl Med       Date:  1997-12       Impact factor: 10.057

5.  The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.

Authors:  Wouter van Elmpt; Dirk De Ruysscher; Anke van der Salm; Annemarie Lakeman; Judith van der Stoep; Daisy Emans; Eugène Damen; Michel Öllers; Jan-Jakob Sonke; José Belderbos
Journal:  Radiother Oncol       Date:  2012-04-06       Impact factor: 6.280

6.  Is (18)F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models.

Authors:  Nicolas Christian; Stéphanie Deheneffe; Anne Bol; Marc De Bast; Daniel Labar; John A Lee; Vincent Grégoire
Journal:  Radiother Oncol       Date:  2010-03-19       Impact factor: 6.280

7.  Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck.

Authors:  Sungheon Kim; Laurie Loevner; Harry Quon; Eric Sherman; Gregory Weinstein; Alex Kilger; Harish Poptani
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

8.  18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome.

Authors:  Bianca A W Hoeben; Esther G C Troost; Paul N Span; Carla M L van Herpen; Johan Bussink; Wim J G Oyen; Johannes H A M Kaanders
Journal:  J Nucl Med       Date:  2013-01-23       Impact factor: 10.057

Review 9.  Value of whole-body FDG PET in management of lung cancer.

Authors:  Kotaro Higashi; Ichiro Matsunari; Yoshimichi Ueda; Ryosuke Ikeda; Jianfei Guo; Manabu Oguchi; Hisao Tonami; Itaru Yamamoto
Journal:  Ann Nucl Med       Date:  2003-02       Impact factor: 2.668

10.  Comparison of [18F]FDG uptake and distribution with hypoxia and proliferation in FaDu human squamous cell carcinoma (hSCC) xenografts after single dose irradiation.

Authors:  Kerstin Bruechner; Ralf Bergmann; Alina Santiago; Birgit Mosch; Ala Yaromina; Franziska Hessel; Frank Hofheinz; Joerg van den Hoff; Michael Baumann; Bettina Beuthien-Baumann
Journal:  Int J Radiat Biol       Date:  2009-09       Impact factor: 2.694

View more
  8 in total

1.  Potential role of functional imaging in predicting outcome for patients treated with carbon ion therapy: a review.

Authors:  Giulia Riva; Sara Imparato; Giovanni Savietto; Mattia Pecorilla; Alberto Iannalfi; Amelia Barcellini; Sara Ronchi; Maria Rosaria Fiore; Chiara Paganelli; Giulia Buizza; Mario Ciocca; Guido Baroni; Lorenzo Preda; Ester Orlandi
Journal:  Br J Radiol       Date:  2021-09-14       Impact factor: 3.039

Review 2.  Recent advances in radiation oncology.

Authors:  Cristina Garibaldi; Barbara Alicja Jereczek-Fossa; Giulia Marvaso; Samantha Dicuonzo; Damaris Patricia Rojas; Federica Cattani; Anna Starzyńska; Delia Ciardo; Alessia Surgo; Maria Cristina Leonardi; Rosalinda Ricotti
Journal:  Ecancermedicalscience       Date:  2017-11-30

3.  Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.

Authors:  Christin Neuber; Birgit Belter; Sebastian Meister; Frank Hofheinz; Ralf Bergmann; Hans-Jürgen Pietzsch; Jens Pietzsch
Journal:  Molecules       Date:  2018-02-17       Impact factor: 4.411

Review 4.  Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?

Authors:  Ruben S A Goedegebuure; Leonie K de Klerk; Adam J Bass; Sarah Derks; Victor L J L Thijssen
Journal:  Front Immunol       Date:  2019-01-14       Impact factor: 7.561

5.  Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients.

Authors:  Geoff S Higgins; Daniel R McGowan; Pauline Bourigault; Michael Skwarski; Ruth E Macpherson
Journal:  EJNMMI Res       Date:  2021-12-29       Impact factor: 3.138

Review 6.  Treatment-integrated imaging, radiomics, and personalised radiotherapy: the future is at hand.

Authors:  Julian Malicki; Tomasz Piotrowski; Ferran Guedea; Marco Krengli
Journal:  Rep Pract Oncol Radiother       Date:  2022-09-19

7.  Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to 177Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor.

Authors:  Mikael Montelius; Johan Spetz; Oscar Jalnefjord; Evelin Berger; Ola Nilsson; Maria Ljungberg; Eva Forssell-Aronsson
Journal:  Transl Oncol       Date:  2018-01-11       Impact factor: 4.243

8.  Does a 6-point scale approach to post-treatment 18F-FDG PET-CT allow to improve response assessment in head and neck squamous cell carcinoma? A multicenter study.

Authors:  P Bonomo; A Merlotti; S Morbelli; V Berti; C Saieva; F Bergesio; A Bacigalupo; L Belgioia; C Franzese; E Lopci; A Casolo; E D'Angelo; D Alterio; L Travaini; L Berretta; V Pirro; S Ursino; D Volterrani; M Roncali; F Vigo; S Cicchetti; F Scalone; G Belli; S Cauda; I Desideri; E Russi; L Livi; A Bianchi
Journal:  Eur J Hybrid Imaging       Date:  2020-05-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.